1. Scrip
  2. >>R&D
  3. >>Clinical Trials

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

‘Highest’ MG-ADL Response Rate

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

Concept of Myasthenia Gravis written on sticky notes isolated on Wooden Table.
RemeGen has shown telitacicept's potenial as a an alternative to FcRn Inhibitors In gMG. • Source: Shutterstock

RemeGen’s telitacicept, the world’s first approved fusion protein targeting B-cell lymphocyte stimulator/a proliferation inducing ligand (BLyS/APRIL), is looking increasingly likely to provide a strong alternative to existing neonatal Fc receptor (FcRn) inhibitors in generalized myasthenia gravis (gMG), new data from a China-only Phase III study suggest.

Key Takeaways
  • RemeGen’s telitacicept looks likely to be a strong alternative to FcRn inhibitors such as argenx’s Vyvgart for generalized myasthenia gravis, based on new data from...

At week 24, patients treated with telitacept subcutaneously once weekly showed improvements of a placebo-adjusted 4.8 points (p<0.001) in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) score, the primary endpoint,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

More from Rare Diseases